158 related articles for article (PubMed ID: 32985337)
1. Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy.
Flynn F; Richard G; Dobrescu MA; Bouchard J; Williamson D; Brindamour D; Charbonney E; Dupuis S
J Pharm Pract; 2022 Apr; 35(2):302-307. PubMed ID: 32985337
[TBL] [Abstract][Full Text] [Related]
2. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
Sheikh-Taha M
Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
[TBL] [Abstract][Full Text] [Related]
3. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
4. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
5. Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses.
George S; Taburyanskaya M; Lewis V
Blood Coagul Fibrinolysis; 2019 Jan; 30(1):42-46. PubMed ID: 30431448
[TBL] [Abstract][Full Text] [Related]
6. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
Comuth WJ; Haase AM; Henriksen LØ; Malczynski J; van de Kerkhof D; Münster AB
Scand J Clin Lab Invest; 2018; 78(1-2):1-5. PubMed ID: 29148292
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
Laxamana LC; Co COC; Yu JRT; Mojica CV; Iboleon-Dy MAM; Domingo AMC; Ilano KCS; Macrohon-Valdez MCZ
Clin Ther; 2020 Sep; 42(9):1840-1845. PubMed ID: 32778345
[TBL] [Abstract][Full Text] [Related]
8. Reversal of Dabigatran Bleeding and Coagulopathy Using Idarucizumab in a Patient With Acute Kidney Injury.
Vidal J; DePalma R; Forouzan L
P T; 2018 Dec; 43(12):748-749. PubMed ID: 30559587
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.
Novak JE; Alamiri K; Yee J
Am J Kidney Dis; 2018 Jan; 71(1):137-141. PubMed ID: 28549534
[TBL] [Abstract][Full Text] [Related]
11. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.
Athavale A; Jamshidi N; Roberts DM
Clin Toxicol (Phila); 2020 Aug; 58(8):789-800. PubMed ID: 32267185
[No Abstract] [Full Text] [Related]
12. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of severe dabigatran intoxication with idarucizumab in a patient with acute kidney injury].
Poulsen CG; Bestle M; Boesby L
Ugeskr Laeger; 2017 Feb; 179(7):. PubMed ID: 28397672
[TBL] [Abstract][Full Text] [Related]
15. A Case of Liver Failure Due to Dabigatran Treated with Venovenous Hemodiafiltration and Idarucizumab.
Guglielmo N; Orso D; Mestroni R; Montanari G
Curr Drug Saf; 2020; 15(3):227-230. PubMed ID: 32576132
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
17. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
[TBL] [Abstract][Full Text] [Related]
18. Life-threatening bleeding due to persistent dabigatran effect in a patient with sepsis despite idarucizumab therapy and haemodialysis.
Humphries K; Huggan P; Stiles M; Martynoga R
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31439551
[TBL] [Abstract][Full Text] [Related]
19. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
[TBL] [Abstract][Full Text] [Related]
20. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
